Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
09. März 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
12. November 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
10. November 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent developments in competitive landscape; data now expected as early as the second...
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
03. November 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
06. Oktober 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of reducing rate of pulmonary exacerbationsLenabasum treatment had a favorable safety profile and was well-toleratedData to be presented at the upcoming North...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
03. August 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
30. Juli 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
29. Juli 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per shareReceived $20 million first tranche from $50 million debt facility with K2 HealthVentures Cash on hand of...
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
22. Juni 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
15. Mai 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 15, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...